Wellington Management Group LLP Cuts Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Wellington Management Group LLP lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 12.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 57,370 shares of the biopharmaceutical company’s stock after selling 7,787 shares during the quarter. Wellington Management Group LLP’s holdings in Halozyme Therapeutics were worth $2,743,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership boosted its holdings in Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock worth $47,470,000 after buying an additional 581,475 shares in the last quarter. Pictet Asset Management Holding SA grew its holdings in shares of Halozyme Therapeutics by 11.5% in the 4th quarter. Pictet Asset Management Holding SA now owns 18,900 shares of the biopharmaceutical company’s stock worth $904,000 after acquiring an additional 1,946 shares during the period. New Age Alpha Advisors LLC purchased a new position in Halozyme Therapeutics in the 4th quarter valued at approximately $1,351,000. Norges Bank acquired a new position in Halozyme Therapeutics during the fourth quarter worth $60,054,000. Finally, EFG Asset Management North America Corp. boosted its position in Halozyme Therapeutics by 18.3% during the fourth quarter. EFG Asset Management North America Corp. now owns 128,294 shares of the biopharmaceutical company’s stock worth $6,133,000 after purchasing an additional 19,881 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now directly owns 185,453 shares in the company, valued at approximately $10,765,546.65. The trade was a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now directly owns 38,611 shares in the company, valued at approximately $2,173,799.30. This represents a 11.46 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,200 shares of company stock worth $1,286,568 in the last 90 days. 2.40% of the stock is owned by company insiders.

Halozyme Therapeutics Stock Up 4.4 %

HALO stock opened at $60.22 on Friday. The company has a 50 day moving average price of $60.22 and a two-hundred day moving average price of $54.93. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock has a market capitalization of $7.44 billion, a P/E ratio of 17.56, a PEG ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The business had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Benchmark restated a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Piper Sandler upped their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Finally, Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.